Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) shares traded up 0.3% during mid-day trading on Wednesday . The company traded as high as $6.89 and last traded at $6.88. 1,315,522 shares traded hands during mid-day trading, a decline of 21% from the average session volume of 1,663,260 shares. The stock had previously closed at $6.86.

A number of research analysts have recently issued reports on the stock. ValuEngine raised shares of Marinus Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Tuesday, July 25th. JMP Securities reaffirmed an “outperform” rating and issued a $11.00 price objective (up previously from $5.00) on shares of Marinus Pharmaceuticals in a research report on Tuesday, September 12th.

The firm has a 50 day moving average of $4.13 and a 200-day moving average of $2.18. The company’s market cap is $200.52 million.

Marinus Pharmaceuticals (NASDAQ:MRNS) last issued its earnings results on Tuesday, August 1st. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.27) by $0.06. On average, analysts expect that Marinus Pharmaceuticals, Inc. will post ($0.74) earnings per share for the current year.

A number of institutional investors have recently made changes to their positions in MRNS. KCG Holdings Inc. increased its stake in Marinus Pharmaceuticals by 29.5% in the first quarter. KCG Holdings Inc. now owns 64,539 shares of the biopharmaceutical company’s stock valued at $114,000 after purchasing an additional 14,692 shares during the last quarter. Nexthera Capital LP purchased a new position in Marinus Pharmaceuticals in the first quarter valued at approximately $1,416,000. Finally, Jennison Associates LLC increased its stake in Marinus Pharmaceuticals by 108.1% in the second quarter. Jennison Associates LLC now owns 811,665 shares of the biopharmaceutical company’s stock valued at $1,112,000 after purchasing an additional 421,600 shares during the last quarter. Institutional investors own 23.61% of the company’s stock.

WARNING: “Marinus Pharmaceuticals, Inc. (MRNS) Trading 0.3% Higher” was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this article on another website, it was illegally stolen and reposted in violation of US & international copyright law. The legal version of this article can be viewed at https://www.thecerbatgem.com/2017/10/06/marinus-pharmaceuticals-inc-mrns-trading-0-3-higher.html.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical-stage product candidate, ganaxolone, is a modulator being developed in various dose forms, including intravenous, oral capsule and oral liquid, intended to provide more treatment options to adult and pediatric patient populations in both acute and chronic care settings.

Receive News & Stock Ratings for Marinus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.